Company Encyclopedia
View More
name
Centessa Pharmaceuticals
CNTA.US
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment.
1.907 T
CNTA.USMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
C
BiotechnologyIndustry
Industry Ranking74/396
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-60.62%E
    • Profit Margin-1617.99%E
    • Gross Margin0.00%E
  • Growth ScoreB
    • Revenue YoY118.88%A
    • Net Profit YoY-50.50%D
    • Total Assets YoY-26.47%E
    • Net Assets YoY-39.58%E
  • Cash ScoreB
    • Cash Flow Margin-6.18%D
    • OCF YoY118.88%A
  • Operating ScoreE
    • Turnover0.03E
  • Debt ScoreB
    • Gearing Ratio32.73%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Centessa Pharmaceuticals Chief Technology & Quality Officer Tia L. Bush Reports Sale of Common Shares

    Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals, reported the sale of common shares. The information was published via EDGAR by Centessa Pharmaceuticals on November 18, 2025. This brief was created by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    CNTA
    +1.60%
    Reuters·
    US
    CNTA
    +1.60%

    Centessa Pharmaceuticals (CNTA) Gets a Buy from Guggenheim

    Guggenheim maintains a Buy rating on Centessa Pharmaceuticals with a $43.00 price target. The stock closed at $27.32, with a Strong Buy consensus and a $37.10 average price target, indicating a 35.80% upside. Wells Fargo also maintains a Buy rating with a $35.00 target.

    Tip Ranks·
    US
    CNTA
    +1.60%
    Tip Ranks·
    US
    CNTA
    +1.60%

    Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of "Moderate Buy" from Analysts

    Centessa Pharmaceuticals PLC (NASDAQ:CNTA) has received a consensus rating of "Moderate Buy" from twelve research firms. Analysts have set an average 12-month target price of $33.11. Recent insider transactions include sales by Mario Alberto Accardi and CTO Tia L. Bush. Institutional investors own 82.01% of the company's stock. Centessa Pharmaceuticals reported a quarterly loss of $0.41 per share, missing estimates by $0.02.

    Market Beat·
    US
    CNTA
    +1.60%
    Market Beat·
    US
    CNTA
    +1.60%

    Lifesci Capital Issues Optimistic Forecast for CNTA Earnings

    Lifesci Capital has raised its FY2025 earnings estimates for Centessa Pharmaceuticals, now expecting an EPS of ($1.37), up from ($1.39). The firm maintains a "Strong-Buy" rating on the stock. Centessa's stock has a consensus target price of $33.11, with an average rating of "Moderate Buy." Recent insider trading and institutional investments indicate significant interest in the company. The stock opened at $27.61, with a market cap of $3.70 billion.

    Market Beat·
    US
    CNTA
    +1.60%
    Market Beat·
    US
    CNTA
    +1.60%

    Centessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

    Wells Fargo & Company raised their price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $30.00 to $35.00, giving the stock an "overweight" rating. This suggests a potential upside of 31.89% from its current price. Other analysts also have positive ratings on CNTA, with a consensus rating of "Moderate Buy" and an average target price of $33.11. Centessa Pharmaceuticals' stock is currently trading at $26.54, with a market cap of $3.55 billion.

    Market Beat·
    US
    CNTA
    +1.60%
    Market Beat·
    US
    CNTA
    +1.60%